Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches

摘要: Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL a very limited prognosis. A better understanding of the complex biology has already led approval several innovative agents, expanding landscape therapies and improving therapeutic options especially refractory/relapsed (R/R) disease. Nevertheless, further optimise treatment, early identification individual risk profile risk-adapted, patient-tailored choice strategy needs be prospectively incorporated into clinical patient management. The present review highlights recent advances in deciphering molecular background MCL, definition prognostically relevant factors potential druggable targets summarises current treatment recommendations primary R/R including novel targeted therapies.